What is the right way to administer pegylated liposomal doxorubicin in breast cancer therapy?

Journal of Clinical Oncology

Volumn 28, Issue 12, 2010, Pages

  Grenader, Tal ^a   Gabizon, Alberto ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; DRUG DERIVATIVE; MACROGOL DERIVATIVE; TAXOID;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BREAST CANCER; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG UPTAKE; DRUG WITHDRAWAL; ERYTHEMA; HUMAN; KAPOSI SARCOMA; LETTER; LOADING DRUG DOSE; METASTASIS; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SINGLE DRUG DOSE; SKIN DISEASE; SURVIVAL; ANIMAL; BREAST TUMOR; DOSE RESPONSE; FEMALE; MAXIMUM TOLERATED DOSE; NOTE; TREATMENT OUTCOME;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; POLYETHYLENE GLYCOLS; TAXOIDS; TREATMENT OUTCOME;

EID: 77951645729     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.8052     Document Type: Letter

References (17)

1. Sparano JA, Makhson AN, Semiglazov VF, et al: Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: Results from a randomized phase III study. J Clin Oncol 27:4522-4529, 2009
2. Sparano JA, Malik U, Rajdev L, et al: Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer. J Clin Oncol 19:3117-3125, 2001 (Pubitemid 32565450)
3. Pavlick AC, Chodkiewicz C, Liebes L, et al: A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factor. Anticancer Drugs 15:119-125, 2004 (Pubitemid 38316744)
4. Briasoulis E, Pentheroudakis G, Karavasilis V, et al: Weekly paclitaxel combined with pegylated liposomal doxorubicin (CaelyxTM) given every 4 weeks: Dose-finding and pharmacokinetic study in patients with advanced solid tumors. Ann Oncol 15:1566-1573, 2004 (Pubitemid 39409749)
5. Lyass O, Uziely B, Ben-Yosef R, et al: Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 89:1037-1047, 2000
6. Briasoulis E, Karavasilis V, Tzamakou E, et al: Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel. Cancer Chemother Pharmacol 53:452-457, 2004 (Pubitemid 38553669)
7. Lyass O, Hubert A, Gabizon AA: Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies. Clin Cancer Res 7:3040-3046, 2001 (Pubitemid 32963822)
8. Pignata S, Lauraine EP, du Bois A, et al: Pegylated liposomal doxorubicin combined with carboplatin: A rational treatment choice for advanced ovarian cancer. Crit Rev Oncol Hematol 73:23-30, 2010
9. Alberts DS, Muggia FM, Carmichael J, et al: Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol 31:53-90, 2004 (Pubitemid 40023242)
10. Cabanes A, Tzemach D, Goren D, et al: Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model. Clin Cancer Res 4:499-505, 1998 (Pubitemid 28122769)
11. Colbern GT, AJH, Musterer RS, et al: Working significant increase in antitumor potency of doxorubicin Hc1 by its encapsulation in pegylated liposomes. J Liposome Res 9:523-538, 1999
12. Gabizon A, Tzemach D, Mak L, et al: Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. J Drug Target 10:539-548, 2002 (Pubitemid 36124352)
13. Amantea MA, Forrest A, Northfelt DW, et al: Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma. Clin Pharmacol Ther 61:301-311, 1997 (Pubitemid 27145431)
14. Uziely B, Jeffers S, Isacson R, et al: Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 13:1777-1785, 1995
15. Hamilton A, Biganzoli L, Coleman R, et al: EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer European Organisation for Research and Treatment of Cancer. Ann Oncol 13:910-918, 2002 (Pubitemid 34752687)
16. Gabizon A, Isacson R, Rosengarten O, et al: An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin. Cancer Chemother Pharmacol 61:695-702, 2008
17. O'Brien ME, Wigler N, Inbar M, et al: Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15:440-449, 2004 (Pubitemid 38444547)